Marketing Buprenorphine for Chronic Pain Management: Overcoming Societal Perceptions and Enhancing Public Health
DOI:
https://doi.org/10.14738/abr.1305.18834Keywords:
chronic pain, perception, buprenorphine, marketing, opioid use disorder, Health Belief ModelAbstract
As a partial mu-opioid receptor agonist, buprenorphine is safe and effective in lowering the risk of opioid dependency, making it a valuable tool for treating pain. Buprenorphine’s comparative advantages over typical opioids—such as a lower risk of abuse and a good safety profile—are highlighted in the literature review. Despite these advantages, medical and cultural stigma prevents eligible patients from effectively using this medicine. As such, stigma impacts both healthcare providers' views toward prescribing this medication and patients' access to therapy. Using a methodology of thoroughly understanding buprenorphine's potential to redefine therapeutic strategies in public health, this study examines the pharmacological foundations, compare its efficacy and safety with other analgesics, and explore remedies for the stigmas associated with its use This exploratory paper, through literature review of existing data, investigates the multifaceted role of buprenorphine in the management of chronic pain and treating opioid use disorder, emphasizing the challenges posed by stigma and regulatory barriers. This study’s findings lead to a discussion of how academics and marketers may improve public awareness and proper use of buprenorphine by developing educational initiatives. It is recommended that marketers create focused educational initiatives for the public and healthcare professionals with the goal of changing public opinion and raising awareness of buprenorphine as an essential treatment option. It is the responsibility of academics to close research gaps, especially in the areas of understanding and combating stigma via empirical investigations and the use of theoretical frameworks such as the Health Belief Model. The original study advocates for a comprehensive strategy that combines legislative change, activism, and ongoing research to optimize buprenorphine's potential and enhance public health outcomes related to pain treatment and opiate addiction.
References
Bish, A., Sutton, S., & Golombok, S. (2000). Predicting uptake of a routine cervical smear test: A comparison of the Health Belief Model and the Theory of Planned Behaviour. Psychology and Health, 15(1), 35-50. https://doi.org/10.1080/08870440008400288
Carpenter, C. J. (2010). A meta-analysis of the effectiveness of health belief model variables in predicting behavior. Health Communication, 25(8), 661-669. https://doi.org/10.1080/10410236.2010.521906
Centers for Disease Control and Prevention. (2022). Clinical practice guideline for prescribing opioids for pain — United States, 2022. MMWR Recommendations and Reports, 71(3). https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm
Champion, V. L., & Skinner, C. S. (2008). The Health Belief Model. In K. Glanz, B. K. Rimer, & K. Viswanath (Eds.), Health Behavior and Health Education: Theory, Research, and Practice (4th ed., pp. 45-65). Jossey-Bass.
Cheetham, A., Picco, L., Barnett, A., Lubman, D. I., & Nielsen, S. (2022). The Impact of Stigma on People with Opioid Use Disorder, Opioid Treatment, and Policy. Substance Abuse and Rehabilitation, 13, 1-12. https://doi.org/10.2147/sar.s304566
Chen, K. Y., Chen, L., & Mao, J. (2014). Buprenorphine–Naloxone Therapy in Pain Management. Anesthesiology, 120(5), 1262-1274. https://doi.org/10.1097/aln.0000000000000170
Dalal, S., Chitneni, A., Berger, A. A., Orhurhu, V., Dar, B., Kramer, B., Nguyen, A., Pruit, J., Halsted, C., Kaye, A. D., & Hasoon, J. (2021). Buprenorphine for Chronic Pain: A Safer Alternative to Traditional Opioids. Health Psychology Research, 9(1). https://doi.org/10.52965/001c.27241
Dela Cruz, A. M., Karns-Wright, T., Kahalnik, F., Walker, R., Lanham, H. J., Potter, J. S., & Trivedi, M. H. (2023). Stigma towards opioid use disorder in primary care remain a barrier to integrating software-based measurement-based care. BMC Psychiatry, 23(1). https://doi.org/10.1186/s12888-023-05267-w
Dowell, D., Ragan, K. R., Jones, C. M., Baldwin, G. T., & Chou, R. (2022). CDC Clinical Practice Guideline for Prescribing Opioids for Pain—United States, 2022. Morbidity and Mortality Weekly Report. Recommendations and Reports, 71(3), 1–95. https://doi.org/10.15585/mmwr.rr7103a1
Hale, M., Garofoli, M., & Raffa, R. B. (2021). Benefit-Risk Analysis of Buprenorphine for Pain Management. Journal of Pain Research, 14, 1359-1369. https://doi.org/10.2147/jpr.s305146
Heidbreder, C., Fudala, P. J., & Greenwald, M. K. (2023). History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder. Drug Alcohol Depend Rep, 6, 100133. https://doi.org/10.1016/j.dadr.2023.100133
Janet Ho, J., Jones, K. F., Sager, Z., Neale, K., Childers, J. W., Loggers, E., & Merlin, J. S. (2022). Barriers to Buprenorphine Prescribing for Opioid Use Disorder in Hospice and Palliative Care. Journal of Pain and Symptom Management, 64(2), 119-127. https://doi.org/10.1016/j.jpainsymman.2022.05.004
Javed, S., Batool, N., Kamal, N., & Mujtaba, B. G. (2024). Impediments to physicians’ workplace contentment and wellness: A multifaceted qualitative inquiry. Health Economics and Management Review, 5(3), 20-39. https://doi.org/10.61093/hem.2024.3-02.
Johnson, R. E., Fudala, P. J., & Payne, R. (2005). Buprenorphine: Considerations for Pain Management. Journal of Pain and Symptom Management, 29(3), 297-326. https://doi.org/10.1016/j.jpainsymman.2004.07.005
Jones, C. L., Jensen, J. D., Scherr, C. L., Brown, N. R., Christy, K., & Weaver, J. (2015). The Health Belief Model as an explanatory framework in communication research: Exploring parallel, serial, and moderated mediation. Health Communication, 30(6), 566-576. https://doi.org/10.1080/10410236.2013.873363
Jones, C. M., Olsen, Y., Ali, M. M., Sherry, T. B., McAninch, J., Creedon, T., Juliana, P., Jacobus-Kantor, L., Baillieu, R., Diallo, M. M., Thomas, A., Gandotra, N., Sokolowska, M., Ling, S., & Compton, W. (2023). Characteristics and Prescribing Patterns of Clinicians Waivered to Prescribe Buprenorphine for Opioid Use Disorder Before and After Release of New Practice Guidelines. JAMA Health Forum, 4(7), e231982. https://doi.org/10.1001/jamahealthforum.2023.1982
Khanfar, N. M., Nafei, W. A., & Mujtaba, B. G. (2024). Impact of digital twinning on health service quality and sustainable competitive advantage: A study with private hospital professionals. Health Economics and Management Review, 5(4), 126-141. https://doi.org/10.61093/hem.2024.4-08.
Kumar, R., Viswanath, O., & Abdolreza Saadabadi. (2023). Buprenorphine. Nih.gov; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK459126/
Lawrence, E., Tworoger, L.C., Ruppel, C.P., and Mujtaba, B.G. (2022). A Team-Based Roadmap for Healthcare Change in a Turbulent Environment: A Longitudinal Study of a Not-for-Profit Hospital Transitioning into a for-Profit Organization. Public Organization Review, 22, 967-985. https://doi.org/10.1007/s11115-021-00544-2
Lazaridou, A., Paschali, M., Edwards, R. R., & Gilligan, C. (2020). Is Buprenorphine Effective for Chronic Pain? A Systematic Review and Meta-analysis. Pain Medicine, 21(12), 3691-3699. https://doi.org/10.1093/pm/pnaa089 Ling, Walter, Hillhouse, Maureen, Jenkins, Jessica, Miotto, Karen, Torrington, Matthew & Chapleo, Christopher. (2012). Comparisons of Analgesic Potency and Side Effects of Buprenorphine and Buprenorphine With Ultralow-dose Naloxone. Journal of Addiction Medicine, 6, 118-123. https://doi.org/10.1097/ADM.0b013e31824fceca
Mujtaba, B. G. and Meyer, C. (2022). Checklist for Professional Communication: A Path to a Healthy Personality, Reflective Mindfulness, and Self-Development Management. Health Economics and Management Review, 3(3), 99-108. https://doi.org/10.21272/hem.2022.3-10
Mujtaba, B.G., Kaifi, B.A., & Lawrence, E. (2023). Safety mandates, legal requirements, and management practices to provide employees with a safe and healthful work environment. International Journal of Occupational and Environmental Safety, 7(2), 1-19. DOI: 10.24840/2184-0954_007-002_002116
Orji, R., Vassileva, J., & Mandryk, R. (2012). Towards an effective health interventions design: An extension of the Health Belief Model. Online Journal of Public Health Informatics, 4(3). https://doi.org/10.5210/ojphi.v4i3.4321
Sivils, A., Lyell, P., Wang, J. Q., & Chu, X.-P. (2022). Suboxone: History, controversy, and open questions. Frontiers in Psychiatry, 13. https://doi.org/10.3389/fpsyt.2022.1046648
Steenhof, N., & Ng, K. (2024). Buprenorphine-naloxone in chronic pain: Overcoming stigma for safer opioid management. Canadian Pharmacists Journal / Revue des Pharmaciens du Canada, 157(1), 7-9. https://doi.org/10.1177/17151635231214508
Substance Abuse and Mental Health Services Administration. (2024). Buprenorphine. https://www.samhsa.gov/medications-substance-use-disorders/medications-counseling-relatedconditions/buprenorphine#:~:text=Generic%20Buprenorphine%2Fnaloxone%20sublingual%20tablets,Buprenorphine%20sublingual%20tablets%20(Subutex)
U.S. Food and Drug Administration. (2023). Information about Medication-Assisted Treatment. https://www.fda.gov/drugs/information-drug-class/information-about-medication-assisted-treatment-mat
Whelan, P. J., & Remski, K. (2012). Buprenorphine vs methadone treatment: A review of evidence in both developed and developing worlds. J Neurosci Rural Pract, 3(1), 45-50. https://doi.org/10.4103/0976-3147.91934
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Marc Perez-Espinosa, Nile M. Khanfar, Omar F. Attarabeen, Huy Pham, Georgina Silva-Suarez, Bahaudin G. Mujtaba
This work is licensed under a Creative Commons Attribution 4.0 International License.
